Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
- Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
- Integra LifeSciences price target raised to $60 from $50 at Citi
- Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates
- Integra LifeSciences plans $150M share repurchase